Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to learn if a pain medication called liposomal bupivacaine (brand name EXPAREL®) with epinephrine will provide better pain control, increased activity, and reduced use of opioids compared with the standard treatment for patients age 6 years and older with cleft lip and palate who have had an alveolar bone graft surgery. Investigators will look at: - pain scores at hip and jaw sites - opioid use in amount and frequency - scores on activity questionnaires Researchers will compare the results of these items with those of patients who had the standard treatment of bupivacaine with epinephrine.


Clinical Trial Description

The study is a randomized, double-blinded trial comparing liposomal bupivacaine (EXPAREL®) with epinephrine (0.25%) local anesthetic with the standard treatment of bupivacaine with epinephrine (0.25%) local anesthetic. The study will enroll patients with cleft lip and palate undergoing an alveolar bone graft (ABG) surgery. Researchers will enroll a maximum of 60 patients from Shriners Children's Chicago over a 2-year period. After this surgery, patients experience significant pain. Considering both the frequency of reported pain after ABG combined with the current opioid crisis and subsequent recommendations by organizations such as the American Society of Anesthesiologists Task Force on Acute Pain Management and Guidelines from the Society for Pediatric Anesthesia for alternative pain management, the use of liposomal bupivacaine (EXPAREL®) is a potential alternative to reduce post-operative pain in the pediatric ABG population. Liposomal bupivacaine (LB) is an injectable form of bupivacaine used at the surgical site and that is released over time. Studies have shown that LB better controls pain, especially during the first 24 hours post-surgery. Better pain control has been associated with a reduction in opioid usage and its associated complications. The study is designed to randomize patients to either the standard of care (bupivacaine with epinephrine) or liposomal bupivacaine with epinephrine to better study pain management within the first five days after ABG surgery in Shriners' cleft lip and palate patients. The FDA approved EXPAREL® for the adult population in 2011 and for the pediatric population, age 6 years and older in 2021. It is a locally injected single dose analgesia that is released over 72 hours. The study is considered minimal risk because LB use does not present an increased risk over the standard of care (standard bupivacaine) as it is an alternative form of the same pain medication. Previous studies have shown no additional risk to using the liposomal version of bupivacaine vs standard bupivacaine in ABG surgeries. Patients will participate up to 5 days following surgery (surgery day is considered day 0) with reported pain, activity scores, and opioid use collected through either paper, electronic, or phone questionnaires. Surgeons and patients will be unaware of which cohort the patient will be randomized to be part of. The pharmacist, anesthesiologist, and research coordinator may all be aware of which drug is administered. Researchers will obtain informed consent from the participants and/or their legally authorized representatives before surgery. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06284434
Study type Interventional
Source Shriners Hospitals for Children
Contact
Status Active, not recruiting
Phase Phase 3
Start date April 24, 2024
Completion date April 24, 2026

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05876169 - How Does Orthognathic Surgery Affect Jaw and Neck Motor Function? N/A
Recruiting NCT04455035 - DynaCleft® Effects on Soft Tissues and on Quality of Life for Incomplete Unilateral Cleft Lip Infants N/A
Not yet recruiting NCT05031039 - Skeletal and Dental Maturational Stages in a Sample of Egyptian Subjects With Cleft Lip and Palate Deformity
Recruiting NCT03839290 - Development of the Palate in Bilateral Orofacial Cleft Newborns One Year After Early Neonatal Cheiloplasty
Recruiting NCT04771156 - Ketorolac in Palatoplasty Phase 4
Completed NCT04725370 - Characterization of Cleft Lip and Palate Conditions in Guatemala
Enrolling by invitation NCT02702869 - Allied Cleft & Craniofacial Quality-Improvement and Research Network (ACCQUIREnet)
Active, not recruiting NCT05971914 - Alveolar Cleft Hard- and Soft Tissue Reconstruction With an Autogenous Tooth Derived Particulate Graft N/A
Completed NCT03708406 - Otologic and Rhinologic Outcomes in Children With Clef Palate
Recruiting NCT06105099 - Effect of Performance-specific Cleft Speech Intervention and Long-term Learning in Children With a Cleft Palate N/A
Completed NCT06075069 - Evaluation of the Effect of Prosthetic Management for Congenital Cleft Lip and Palate Infants on the Middle Ear Function N/A
Completed NCT04384276 - Weigh Easy: Simplifying Home Weight Monitoring for Infants N/A
Recruiting NCT04619030 - Augmented Reality (AR): The Future of "Patient Information Leaflets N/A
Recruiting NCT03065686 - Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing N/A
Completed NCT02845193 - Effect of Novel Nasoalveolar Molding Techniques on Parents' Satisfaction and Short Term Treatment Outcomes in Unilateral Cleft Lip and Palate Infants: A Randomized Controlled Trial N/A
Completed NCT03308266 - Electromyographic Analysis of the Masticatory Muscles in Cleft Lip and Palate Children With Temporomandibular Disorders N/A
Completed NCT01932164 - Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate Patients N/A
Not yet recruiting NCT06411444 - Effect of Different Nasal Stent Designs With Nasoalveolar Molding Appliance N/A
Not yet recruiting NCT06292234 - Patient Specific Implant Versus Miniplates for Advancement of Hypoplastic Maxilla N/A
Recruiting NCT05081258 - Influence of Presurgical Orthodontic Molding on the Growth of Newborns With Unilateral Cleft Lip Palate N/A